SNPMiner Trials (Home Page)
Report for Mutation G13D
 Developed by Shray Alag, 2020.
SNP Clinical Trial Gene 
There are 3 clinical trials
Clinical Trials
      This national, multicenter, open-label phase 2 study without any control arm aims to evaluate
      the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in
      subjects with K-RAS mutated and FcγRIIa polymorphism tumors, in which there is no therapeutic
      alternative for treatment. Failure of the first and second line conventional therapeutic
      lines was documented.
    
All subjects were analyzed and classified as carriers of every different polymorphism of FCy Receptors: for FCyRIIa (H/H, homozygous alleles with histidine and R/H, heterozygous alleles with arginine/histidine) and FCyRIIIa (V/V, homozygous alleles with valine, F/F, homozygous alleles with phenylalanine and F/V, heterozygous alleles with valine ⁄ phenylalanine) (units: subjects with every type of polymorphism) .The FCyR genotype was determined using a TaqMan Allelic Discrimination Assay..
Overall Survival (OS) Related to Codon G13D. --- G13D --- 
  Primary Outcomes 
 Description: Overall survival was defined as the time from date of informed consent signature until death.
 Measure: Overall Survival (OS) Time
 Time: From the date of informed consent signature until death, assessed up to 3 years
  Secondary Outcomes 
 Description: DCR was defined as those subjects achieving complete response (CR), partial response (PR) or stable disease (SD), according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). For target lesions (TLs), CR was defined as the disappearance of all TLs; PR was defined as at least a 30 percent (%) decrease in the sum of longest diameter (SLD) of the TLs, taking as a reference the baseline (BL) SLD; Stable disease (SD) was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For non-target lesions (NTLs), CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and progressive disease (PD) was defined as the appearance
 Measure: Percentage of Subjects With Disease Control Rate (DCR)
 Time: From the date of informed consent signature until progressive disease, assessed up to 3 years
 Description: PFS was defined as the time from informed consent signature until PD or death, whatever occurred first. Subjects who did not have disease progression or were lost to follow-up, were censored at the date of last contact, known to be alive and progression free; moreover, those subjects who started a new treatment (different from cetuximab), were censored at the date of starting the new treatment. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from BL or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.
 Measure: Progression Free Survival (PFS) Time
 Time: From the date of informed consent signature until progressive disease (PD) or death, assessed up to 3 years
 Description: An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
 Measure: Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, AEs Leading to Death
 Time: From the date of enrollment up to 30 days after the last dose of study drug administration, assessed up to 3 years
 Description: The antibody fragment C portion (FCy) of cetuximab interacts with Fc-gamma receptors (FCyRs) expressed by immune effector cells. Polymorphisms were described in genes coding for FCyRIIa and in FCyRIIIa. A histidine/arginine polymorphism at position 131 for FCyRIIa gene and valine ⁄ phenylalanine polymorphism at position 158 for the FCyRIIIa gene were reported to be functionally relevant in the ADCC mechanism. All subjects were analyzed and classified as carriers of every different polymorphism of FCy Receptors: for FCyRIIa (H/H, homozygous alleles with histidine and R/H, heterozygous alleles with arginine/histidine) and FCyRIIIa (V/V, homozygous alleles with valine, F/F, homozygous alleles with phenylalanine and F/V, heterozygous alleles with valine ⁄ phenylalanine) (units: subjects with every type of polymorphism) .The FCyR genotype was determined using a TaqMan Allelic Discrimination Assay.
 Measure: Number of Subjects With Fcγ Receptors (FCγR) IIa/IIIa Polymorphisms
 Time: Baseline
 Description: OS was defined as the time from informed consent signature until death. Subjects without death were censored at the last date known alive (within the study).
 Measure: Overall Survival (OS) Related to Codon 
G13D Time: From the date of informed consent signature until death, lost-to-follow-up or end of study, whatever occurred first (maximal up to 3 years)
 Description: OS was defined as the time from informed consent signature until death. Subjects without death were censored at the last date known alive (within the study).
 Measure: Overall Survival (OS) Related to Killer Inhibitory Receptors 2DS4 (KIR2DS4) Functional Receptor (f/d) and Non-functional Receptor (NFR)
 Time: From the date of informed consent signature until death, lost-to-follow-up or end of study, whatever occurred first (maximal assessed up to 3 years)
 Measure: Beta 2-microglobulin
 Time: Baseline, Week 8
2 Comparison of KRAS/BRAF Mutational Status Between Tumor Tissue Section Analysis With Conventional Techniques and Plasma Samples Analysis (KPLEX2) 
      The goal of this multicenter prospective study is to validate, and ultimately translate in
      routine clinical practice, the use of plasma analysis of ccfDNA for the determination of KRAS
      mutation status in mCRC patients.
    
NCT02784639  Colorectal Cancer  Other: Plasma Analysis of circulating cell free DNA  Other: Tumor tissue analysis of circulating cell free DNA MeSH: Colorectal Neoplasms   
HPO: Neoplasm of the large intestine   
As a
      consequence, the method was adapted to detect the six more frequent KRAS mutations in CRC
      (G12D, G12V, G13D, G12S, G12C, G12A) and the BRAF V600E. --- G12D ---  --- G12V ---  --- G13D --- 
  Primary Outcomes 
 Description: Area under the ROC curve of the mutation percentage obtained from plasma ccfDNA analysis
 Measure: Area under ROC curve
 Time: 12 month
3 A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma 
      This study will determine the safety and tolerability and establish a preliminary recommended
      Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab
      infusion.
    
NCT03948763  Neoplasms  Carcinoma, Non-Small-Cell Lung  Pancreatic Neoplasms  Colorectal Neoplasms  Biological: V941  Biological: Pembrolizumab MeSH: Carcinoma, Non-Small-Cell Lung    Colorectal Neoplasms    Pancreatic Neoplasms    Neoplasms   
HPO: Neoplasm    Neoplasm of the large intestine    Neoplasm of the pancreas    Non-small cell lung carcinoma   
All
          -  Has a histologically confirmed advanced or metastatic KRAS 4MUT+ (G12D, G12V, G13D or
             G12C) (4 prevalent KRAS mutant antigens in solid tumors) solid tumor identified by
             local laboratory testing, and who have received, or been intolerant to, or ineligible
             for all treatment known to confer clinical benefit. --- G12D ---  --- G12V ---  --- G13D --- 
  Primary Outcomes 
 Description: The following toxicities graded for severity using NCI Common Terminology for Adverse Events (CTCAE), Version 4.0 will be considered a DLT if judged by the investigator to be possibly related to study investigational products: 1) Grade 4 nonhematologic toxicity (ie. not a laboratory finding). 2) Grade 4 hematologic toxicity lasting ≥ 7 days, except thrombocytopenia: 3) Grade 4 thrombocytopenia of any duration 4) Grade 3 thrombocytopenia associated with clinically significant bleeding 5) Any nonhematologic AE ≥ Grade 3 in severity, with some exceptions 6) Any Grade 3 or Grade 4 nonhematologic laboratory value that meets one of the study criteria 7) Febrile neutropenia Grade 3 or Grade 4 8) Prolonged delay (> 2 weeks) in initiating Cycle 2 due to treatment-related toxicity. 9) Any treatment-related toxicity that causes the participant to discontinue treatment during Cycle 1. 10) Grade 5 toxicity 11) Any other clinically significant toxicity judged to be a DLT by the investigator.
 Measure: Dose-Limiting Toxicities (DLTs)
 Time: Cycle 1 (Up to 21 days)
 Description: Number of participants who experienced an AE. An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
 Measure: Adverse Events (AEs)
 Time: Up to approximately 25 months
 Description: Number of participants who discontinued from study due to an AE. An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
 Measure: Discontinuations
 Time: Up to approximately 24 months
  Secondary Outcomes 
 Description: ORR is assessed by the investigator based on Response Rate Assessed by Modified Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) and RECIST for immune-based therapeutics (iRECIST) following administration of V941 in combination with pembrolizumab. Objective response is a confirmed complete response (CR) or partial response (PR).
 Measure: Objective Response Rate (ORR)
 Time: Up to approximately 24 months
 Description: Presence of and changes in the quantity of mutant KRAS specific T cells in the blood.
 Measure: Mutant KRAS Specific T cells
 Time: Up to approximately 24 months
  Other Outcomes 
 Description: T-cell receptor (TCR) clonality and diversity in the periphery and tumor.
 Measure: T-cell receptor (TCR)
 Time: Up to approximately 24 months
HPO Nodes
Neoplasm of the large intestine 
Genes 120
FLCN  SDHC  MLH1  PMS2  APC  EPCAM  SDHC  PALLD  SRC  BUB1  APC  GREM1  NTHL1  PMS1  PTEN  SDHB  MSH6  APC  KIT  SDHD  KRAS  BMPR1A  FAN1  CTNNB1  MSH3  POLD1  KRAS  RNF43  KEAP1  DICER1  DLC1  BMPR1A  MSH2  MSH6  PIK3CA  CDKN2A  FGFR3  BMPR1A  MUTYH  PIK3CA  BMPR1A  EP300  FOXE1  ENG  SMAD7  AXIN2  CHEK2  MLH1  RPS20  BRCA1  RPS19  PRKAR1A  APC  GPR35  MLH1  AKT1  POLE  SMAD4  KIT  TP53  TRIP13  COL14A1  MDM2  SMAD4  POLE  BRCA2  AKT1  MSH6  HABP2  NRAS  MUTYH  BUB1B  DOCK8  TGFBR2  STK11  AXIN2  EPCAM  BUB3  DCC  AXIN2  TCF4  KLLN  MSH2  APC  TP53  SEC23B  PTEN  TGFBR2  SEMA4A  POLD1  PIK3CA  PDGFRA  MINPP1  APC  SH3KBP1  BMPR1A  TP53  BUB1  AAGAB  SMAD4  BMPR1A  MST1  MLH3  MSH2  PALB2  FLCN  SDHA  PMS2  SDHB  BUB1B  MSH2  MLH1  CEP57  MLH3  TP53  PTPRJ  PMS1  APC  CDKN2A  APC   hr>
Non-small cell lung carcinoma 
Genes 3
TP53  TP53  BAP1   hr>
Neoplasm of the pancreas 
Genes 105
MGMT  BRCA1  MLH1  PMS2  RAD51C  TERC  CDKN2B  PALLD  TSC2  CHEK2  SMAD4  NTHL1  RAD51D  CTC1  MSH6  NOP10  KRAS  NHP2  BAP1  PDGFRB  FAN1  KRAS  BRD4  RNF43  CDKN2B  TP53  MSH2  CDKN2A  SPINK1  RTEL1  CDKN2C  VHL  PIK3CA  CDK4  PARN  BRCA2  KRAS  TERF2IP  CHEK2  CDKN1A  RPS20  BRCA1  USB1  PRKAR1A  POT1  TERT  APC  CDKN2A  CCND1  STK11  TP53  COL14A1  NUTM1  MDM2  TSC1  BRCA2  SLC12A3  EWSR1  CDC73  CDKN1B  ACD  CDC73  BRIP1  MRE11  GCGR  TP53  STK11  EPCAM  MEN1  NPM1  WRAP53  TGFBR2  SEMA4A  TINF2  MITF  BMPR1A  TP53  NOTCH3  DKC1  BARD1  AAGAB  SMAD4  RAD50  STK11  NBN  MLH3  PALB2  PALB2  CDKN2A  WT1  BRCA2  MAFA  MC1R  MEN1  RAD51  CDC73  CLCNKB  TP53  CDKN1B  FLI1  PTEN  PMS1  CDKN2A  TERT  APC   hr>
Neoplasm 
Genes 1473
GPC3  LETM1  LZTS1  REST  MPL  ARID1B  RPL18  MGMT  GLI3  BIRC3  ZSWIM6  TRNS2  ETV6  HNF1B  KIT  BRCA1  SUFU  PLAG1  SOX9  TP63  CTSC  RASA1  ATRX  TRIM37  SUFU  BTK  CYP11B1  NOTCH3  EPCAM  PORCN  PIGL  AR  TET2  FH  TGIF1  HMBS  ATRX  TREX1  SMAD4  KRT17  FGFR1  WDPCP  SF3B1  GPR101  KIT  GLI1  SLC25A11  XRCC4  SDHD  PRKCD  RNF43  SDHB  BAP1  EGFR  PIGA  NF1  ASCL1  MPL  RET  C2CD3  GDNF  NR5A1  DICER1  TNFRSF4  CASP10  TERC  FGF8  PSAP  CIB1  SLC22A18  PTCH2  ENPP1  CDKN2C  SLC25A11  GPR101  KIT  AXIN2  TREX1  DYNC2LI1  ERCC4  RPS14  COMP  TINF2  FOXE1  DHCR24  RPS7  TYROBP  HOXD13  ERBB2  BLK  EYA1  ZFPM2  ERCC6  NLRP1  STAC3  ERCC5  NUTM1  MEN1  WT1  BCL10  GNPTAB  KRAS  TP53  KDR  PUF60  TRNF  FCN3  SDHC  KCNH1  MSTO1  EP300  BUB1B  GNA11  KCNE3  DOCK8  SEMA3C  ACD  GLI2  SMPD1  SUFU  NF1  PTCH2  ACAN  DCC  WT1  CTSA  KIF11  BCR  SRGAP1  KIT  PTEN  LEMD3  MLLT10  SCN4A  BRCA2  BMPR1A  NOTCH3  SEC23A  CDKN1C  BARD1  SPIB  RSPO1  MC2R  CALR  ATP6V1B2  NBN  RAD54L  MST1  SUFU  MYCN  TMEM127  SRD5A3  IGF2  CD28  RUNX1  OGG1  HAX1  SDHC  CTNNB1  MST1R  SDHA  IGF2  KCNJ10  IL12RB1  MEN1  RAD51  TFE3  ND5  MMEL1  MVK  APC  FLI1  RNF6  NF1  BRCA2  SUFU  GPC6  NR4A3  TTC37  KIT  NRTN  BLNK  IGH  SPRED1  TXNRD2  IGF2R  FOXP1  BUB1B  SOS1  LRP5  GJB2  DNMT3A  PMS2  PRKN  RET  MSH6  ACVRL1  MPLKIP  ERCC2  AIP  GNAS  TAL1  NNT  RECQL4  PMS1  DLL1  EIF2AK4  STAT6  MNX1  SDHB  KRAS  MEN1  MN1  SH2B3  EFL1  VHL  KLLN  RMRP  RUNX1  SIX3  GDNF  FANCD2  EXT1  CDH23  BRD4  DLEC1  NODAL  CARMIL2  SDHB  MSH2  HMBS  SMAD4  SRP72  NRAS  DOCK8  SPRTN  BRCA1  MAP2K1  KRT14  LETM1  TERT  MAP2K2  HRAS  WHCR  WT1  IDH1  TMEM107  SCN10A  GJB3  SDHD  KRAS  GATA1  RPS20  GJB2  SLX4  USP8  PRKAR1A  CR2  JAK2  HFE  MPL  POT1  BRCA2  GNAI3  SDHB  ALK  OCA2  TP53  GPC4  ACTG2  CTNNB1  HSPG2  AR  FGFR1  STK4  MET  TMC8  MRAP  MSH6  CCBE1  EWSR1  LMO1  EDN3  LEMD3  PGM3  FGFR3  CASP8  RB1CC1  SCN9A  FANCL  TG  SDHD  COX3  IGF2  COL11A2  AGGF1  GPR101  PRKN  PLCB4  SDHD  NF1  GTF2E2  MAP2K1  ESCO2  CDC73  WRAP53  TET2  PDGFRB  RNASEH2A  RAD21  HNF1A  TGFBR2  POLD1  COX2  TNFRSF10B  MINPP1  DNAJC21  FAS  EXT1  SLC26A2  APC  SDHAF2  TINF2  LIG4  POLR1D  WWOX  TMC6  RPS19  ERCC2  SASH1  MC1R  MVD  SEC23B  CYP2A6  GPC3  KIT  HRAS  RAD54L  SDHA  GDNF  NKX2-1  GFI1  ALX3  STAT3  MYH11  DYNC2LI1  FGFR2  TCOF1  PTEN  MAFA  PIK3R1  SLC25A13  HRAS  VHL  COL7A1  GNAS  FGFR2  PIK3CA  GPC4  DICER1  ERCC3  PIK3CA  RAD51C  RB1  RMRP  MLH3  ATM  COL7A1  LIG4  NF1  VAMP7  RPL35A  RB1  SETD2  BCL10  LPP  NRAS  KRAS  ABCA5  ERCC2  PDE6D  KCNQ1OT1  MS4A1  SLC22A18  APC  LIG4  JAK2  FANCD2  GAS1  STAG3  NRAS  PALLD  SLC22A18  RFWD3  PPP2R1B  APC  PTPN11  PTEN  WIPF1  PIK3CA  NOP10  IL7  UROD  TNFRSF1B  TP53  REST  SLC37A4  NHP2  CXCR4  KIT  CYSLTR2  FZD2  ALX4  BMPR1A  SRY  TRNQ  SDHD  PIGL  CCM2  FIBP  FANCI  GJB4  SPINK1  RPL10  NSD2  MAP3K1  RET  CDK4  HSPA9  TET2  GFI1B  MAD2L2  DCC  AP2S1  SMAD7  BRCA2  TRNK  ERCC3  BRCA1  ELANE  SFTPC  PTH1R  COL1A1  FUZ  OFD1  RET  FLT4  PRKAR1A  SBDS  RPL26  SMARCE1  SMARCAD1  MSH2  BCR  GPR35  INTU  FANCA  STAT1  ANTXR2  FGFRL1  TUBB  BRAF  SLX4  CASP10  TERT  RAD21  MTOR  TRIP13  MYD88  DPM1  RSPO1  PTPN11  CTNNB1  AIP  PTEN  VANGL1  CYP2D6  RPS10  GCK  KRT16  DNAJC21  BCL2  AKT1  KRAS  KLF6  NOTCH1  FLNA  MAX  NF2  PALB2  TP53  PSENEN  RNF6  TSC1  HNF1B  TP53  RFWD3  SDHD  PERP  TP53  DIS3L2  B3GALT6  STS  PDGFB  SMARCB1  BRAF  BRIP1  CBFB  BUB1  BLM  INHBA  CALR  NBN  MLH3  TAF1  MLF1  PIK3CA  MSH2  CTLA4  ND6  PALB2  WT1  PTCH1  POLE  ADA  MC1R  FLT4  ATP7A  MLH3  SMO  TRNF  NRAS  LMNA  DLST  TRNL1  MTAP  TP53  ZAP70  SDHB  CHEK2  PALB2  FLT4  CDK4  NBN  MSR1  CC2D2A  TNPO3  ECE1  RPS15A  NAGS  TMEM67  HNF1A  PIK3CA  ATP7A  AKT1  NRAS  SDHAF2  CXCR4  TSC2  NF2  EPHB2  WDPCP  OFD1  BUB1  FLT3  APC  SMARCA4  CDKN2A  RPS29  MCM4  PDGFRA  ESCO2  CTC1  ESR1  SDHB  MSH6  APC  HABP2  GNAQ  KIF1B  SH3GL1  CD70  MPL  IGH  ZIC2  GCM2  VEGFC  HRAS  CTNNB1  KCNH1  LRRC8A  BRAF  FAS  ICOS  NSD1  RNF43  AKT1  BIN1  DLC1  SH2B3  RARA  WNT10A  CARD14  SDHC  EXOC6B  ESCO2  POLR1C  G6PC  MSH6  KRT1  PDX1  TNFRSF13C  ERCC3  EVC  SNAI2  CD79A  BRCA1  RNASEH2B  CCND1  TP53  RPS19  H19  H19  BRCA2  TFAP2A  ARMC5  FASLG  FGFR3  APC  F5  EDN1  MAP3K8  AIP  APC  AKT1  TERC  CCND1  CEL  MYC  TP53  GPC4  ERCC5  HNF1A  POLE  DAXX  NUP214  TRIP13  AKT1  TET2  CDC73  ND1  MUTYH  PIK3R1  TERT  CEBPA  EXT2  OCRL  DIS3L2  ADAR  TGFBR2  BRCA2  MRE11  SOS1  HNF4A  FAH  TMEM127  WT1  AXIN2  TCF4  EDN3  PTPN3  KRAS  SEMA4A  PIK3CA  XPA  MFN2  TINF2  PIK3CA  APPL1  RUNX1  GNPTAB  FGFR3  NRAS  PDCD10  RAG2  PTEN  CTNNB1  SOX2  BMPR1A  HBB  TERT  USP9X  NFKB1  FANCC  PRF1  WRN  SRY  SRSF2  PMS2  RHBDF2  PHOX2B  RPS17  PAX3  RECQL4  KIF1B  SQSTM1  RB1  EXT1  XPC  CYLD  TOP2A  MYD88  CDKN1B  TET2  GJB2  PTEN  UBE2T  RTEL1  PTCH1  KLHDC8B  GATA1  POLH  JAK2  RHOH  FLCN  DCLRE1C  MTMR14  GTF2H5  PTEN  SBDS  TBC1D24  PAX7  AR  TP53  ASPSCR1  MTM1  RECQL4  ERCC2  TGFBR2  ERCC4  JAK2  SF3B1  CDKN2B  XPC  GATA4  KIT  POU2AF1  BRCA2  GREM1  CDON  NTHL1  DICER1  GINS1  ATM  RAD51D  SHOX  EXT1  RASGRP1  WT1  GATA2  NF2  ERCC4  TUBB  MBTPS2  DHCR7  MYLK  KCNN3  TCTN3  TMEM216  TMEM231  KRT1  CTNNB1  MPL  PDGFRB  FANCG  RPGRIP1L  KEAP1  DICER1  WT1  BAP1  FOXI1  ERCC4  CDKN2A  FGFR3  KDSR  CBL  HRAS  BMPR1A  DISP1  RELA  MAP3K1  PARN  BCR  ENG  COL7A1  LMOD1  KRAS  PAX6  SNAI2  GLI3  FANCF  FOXO1  RPL15  TBX18  TRPV3  PIK3CA  NRAS  CDH1  GNAS  SMARCB1  KLF11  ADA2  EDN3  POU6F2  CDH1  GNAS  IL1B  SMAD4  H19-ICR  SDHB  STK11  NF2  TRIM28  SEC23A  SLCO2A1  BRCA2  BRAF  DNMT3A  MDM2  BMP2  BRCA2  DHH  NRAS  POU6F2  CTBP1  PTCH2  FLCN  CALR  BAP1  LIG4  HRAS  REST  BRAF  SAMD9  NDP  TYR  KRT17  MUC5B  PRSS1  MEN1  NPM1  ITK  MSH2  CYLD  TAL2  SRP54  IFIH1  HMMR  TCTN3  ND5  JAK2  FAM20C  RET  NEK9  DMRT3  KRAS  MINPP1  SH3KBP1  THPO  FAH  KRT5  JAK2  PHKG2  TSC1  TNFRSF13C  MEN1  FH  RPL31  FANCG  PIK3CA  IL2RG  DNAJC21  VANGL2  MYO1H  ALX1  CDKN2A  AIP  H19  NRAS  TWIST1  PTEN  TRNK  TRPS1  RPS26  MAPRE2  RPS27  TCF3  KRT17  ERCC6  DHH  MMP1  FGFR1  SEMA3D  PTCH1  ABL1  CDKN2A  SKI  APC  WWOX  ZSWIM6  NF2  WNT10A  KRAS  GPC3  REST  GJB6  HRAS  VHL  CTNNB1  TGFBR1  IL6  TDGF1  RPL11  IL1RN  BRCA1  MGAT2  POT1  ASCC1  XPA  TBX2  FLCN  HFE  NTHL1  SMARCB1  DVL3  TRNH  IDH1  FANCA  LAMB3  CD79B  RAD51C  PRDM16  PHOX2B  GNAQ  CCL2  PDGFRA  CREB1  SRP54  PIEZO2  TRNL1  GBA  GNAS  WNT5A  PIK3CA  STS  FANCB  KRAS  MAGT1  RAD51  IDH1  TNFRSF13B  TREM2  GABRD  BCL10  SKIV2L  POLD1  KRIT1  KRAS  ARSA  SMAD4  RAD51  TP53  DIS3L2  KIAA0753  PRLR  CD96  LZTR1  WRN  GATA2  EDNRB  MUTYH  ATM  CHIC2  TP53  CYLD  PAX4  SLC26A4  RTEL1  VHL  NEK1  TRNS1  GCM2  TYR  ATP7B  CTHRC1  BRAF  ASXL1  OFD1  MLH1  CDKN1A  PHOX2B  XRCC2  CD19  RB1  FOXC2  TRIM28  EWSR1  TERT  GNA11  F13B  CDKN2A  KARS1  BCL10  TP53  WT1  CDKN2A  FDPS  KIT  COX1  COL14A1  VHL  WT1  TERT  SMAD4  STAR  NUMA1  RPL5  PDGFB  PCGF2  CFTR  KCNQ1OT1  KIT  GJA1  GNAQ  CD27  FANCC  IDH2  EVC2  BRCA2  TCF4  KRAS  PIK3CA  CDC73  ACVR1  BRIP1  TRNW  PRCC  GCGR  CDKN1B  STK11  SCN11A  TGFBR2  AXIN2  ERBB2  RPL35  APC  TSC2  IL12A  SSX2  TET2  KIF1B  DICER1  TRNP  BTK  CCDC22  PDGFRA  ALX3  ADAMTS3  CD81  RET  DKC1  GLI3  FGF3  SMAD4  STK11  ERCC6  WT1  ELANE  C11ORF95  SAMD9L  SLC45A2  NQO2  PTPN11  ATR  PDGFRL  TNFSF12  BRCA2  ADA  BUB1B  FASLG  GDF5  KRAS  CPLANE1  CREBBP  CDC73  CLCNKB  GATA2  CTRC  SDHA  ACTB  APC  BMPER  SPINK1  APC2  MC1R  FOXI1  DYNC2H1  KIT  PPM1D  SDHC  NSD1  SDHC  DDX41  ANTXR1  CASP8  F13A1  SUFU  INS  NUP214  ANTXR2  KIF7  NFKB2  ABCC8  TARS1  ERCC3  TCIRG1  ND4  ERCC2  GNAS  TERT  WASHC5  SLC49A4  RERE  CALR  MSH3  PHOX2B  SLC25A13  BMPR1B  CYLD  SIX6  ASCL1  IDH2  FAN1  CHRNG  CBL  NEUROD1  MSH3  THPO  VANGL1  CDKN2B  TAF15  PTCH2  HMGA2  MSH6  CHEK2  FN1  GATA2  IRF1  KRAS  BMPR1A  NPM1  ERCC3  CDH1  ALK  DNM2  ERBB3  PTPN11  DLST  MUTYH  PARN  GFI1  NBN  FGFR3  CHEK2  EP300  RNF113A  TNFSF15  TEK  TERF2IP  ICOS  COL18A1  TNFSF12  BRAF  CHEK2  IFNG  TMC6  USB1  KDM6B  GJC2  SLC26A2  MDH2  TP53  ENG  MLH1  KRT6B  MNX1  PDGFB  TRNH  POLE  CASP10  HPGD  TET2  RB1  PHOX2B  JAG1  GNB1  ACD  TNFRSF13B  MYC  BRAF  TSC1  SAMD9L  BCL10  H19  POT1  USP8  IGF2  OFD1  CYP11B2  KCNQ1  CDH1  LMX1B  TET2  ANTXR1  JAK2  SMARCB1  ELMO2  PTCH1  SIX1  L2HGDH  WRAP53  BUB3  AXIN1  RET  KCNJ11  ABL1  FANCE  RAD54B  FANCM  TSC2  MAX  IGHM  TSC1  HACE1  CASR  RNF139  MITF  RAF1  WT1  TCTN3  POLH  LIG4  TP53  KRT10  AAGAB  SRY  RAD50  TNFRSF1B  TRNQ  DNASE1L3  FAM149B1  KRT9  VHL  FLCN  TBXT  SLC37A4  DKC1  PNP  DDB2  SETBP1  ECM1  MSH2  CR2  COL2A1  COL7A1  MLH1  FH  SFTPA2  PIK3CA  FOXH1  MET  HNF4A  H19  KAT6B  GPR143  PHB  PMS1  ATP7A  FAT4  TJP2  TFAP2A  GDF2  AHCY  TSC2  CD19  TRNS1  BDNF  TRIP13  AKT1  FGFR2  RAG1  BRCA1  SDHC  MLH1  XRCC3  NSD2  LMNA  SDHC  TERC  EXT2  PIK3CA  MSH3  SDHD  SRC  CHEK2  C1S  ABCA5  HBB  RYR1  FGFR2  CDC73  KIT  FANCE  RET  LYST  KCNJ10  BCHE  HDAC4  INPP5E  CRKL  PHOX2B  BAP1  CPLX1  PDGFRB  ARL6IP6  RNASEL  SETBP1  CTLA4  PALB2  DCLRE1C  NSUN2  XIAP  TRNS2  BMPR1A  IL7R  BCL6  COL4A5  PIK3CA  NOD2  PRKAR1A  NELFA  IL2RG  MYH8  RHBDF2  IGLL1  PIK3CA  SERPINA1  FOXE1  ARHGAP26  TCF4  MITF  ABCB11  ERBB2  GNA14  SLC26A2  NSD1  SH2B3  STK11  PTCH1  GDNF  RPL27  DHCR7  WAS  CIB1  SHH  CACNA1S  LIN28B  SF3B1  ATM  PRKCD  RPS24  LAMA3  ATRX  CASP8  AKT1  OPCML  HFE  SH2D1A  ING1  CCND1  SLC12A3  HABP2  H19  LAMC2  RAD51C  NAB2  NRAS  MAPK1  CPLANE1  CYP26C1  CDKN1B  CHD7  IGH  MYF6  BLM  ASXL1  FH  NEK1  HLA-DRB1  SLC26A4  RPS14  SHOX  RNASEH2C  SMARCD2  GATA2  CDH23  WT1  EPCAM  NR0B1  KLLN  DVL1  SEC23B  GPC3  SLC17A9  BRCA1  SRP54  DKC1  RECQL4  CD28  PTPN11  HRAS  NBEAL2  BARD1  MLH1  DDB2  PMS2  IRF1  ABCC6  EXT2  ASXL1  TSR2  PTEN  MALT1  PTEN  BCR  PALB2  BRIP1  SSX1  PHKA2  FGFR2  SDHB  FERMT1  KCNAB2  FLT3  PMVK  MSTO1  CEP57  MMP1  PICALM  IRF5  TP53  PTPRJ  RNR1  WWOX  PLCD1  RPS28  FGFR3  COL2A1  IKBKG  TERT  RASA1  SAMHD1  PHF21A   hr>